Care that people can use
Home exercise with clinical support, clearer stroke communication, and the gap between a new tool and a better outcome.
In a neck-pain trial, the journey from clinic to home preserved a crucial part of treatment: a therapist still reviewed the exercise programme and decided how it should change. In a trial of genetic guidance for opioid prescribing, the extra information barely changed prescribing. Together, the reports ask a practical question about innovation: does a new tool change the care a person actually receives?
Today's edition follows that question through remote exercise, stroke communication, pain prescribing, swallowing practice, nerve imaging and recovery from bone stress injury. Some findings support a different way to deliver care. Others show uncertain benefit, a measurement that needs clinical interpretation, or a promising idea that has not yet improved the outcome that matters.
All 88 registered sources and 15 study domains were inspected. Discovery produced 811 journal-article metadata records plus one book identifier. Compared with October 15, 161 article records were newly retrieved and 166 left the capped results; these changes are not publication dates or retractions. All 12 inaccessible sources were retried without recovery. The main neck-trial report and displayed tables were read in full through publisher web access. Other research summaries use primary abstracts or subscription previews. Actual AHA communication materials, an ACC announcement, FDA safety notices and a workshop description were read separately. Licensed chapters and unindexed work remain outside verified coverage.
A home programme, with a therapist still in the loop
A two-centre Chinese trial randomized 116 adults aged 18–60 with chronic nonspecific neck pain to sensor-supported home rehabilitation or outpatient care. Both groups received the same twenty-four-week exercise programme. The home system supplied feedback and recommendations; therapists made the final decisions about progression. This was supported rehabilitation, rather than autonomous treatment by an algorithm.
The primary outcome was the Neck Disability Index (NDI), expressed on a 0–100 scale, where lower scores are better. At week 24, the home-minus-outpatient difference was −2.5 percentage points, 95% CI −6.2 to +1.2. The upper confidence limit was below the authors' stated +10-point noninferiority margin. The result met that criterion; it did not demonstrate that home care was superior.
That distinction matters when choosing a service. A person needs to know what support comes with the programme and whether it fits their abilities and circumstances. The word “AI” does not establish that a system can safely diagnose a new problem, select its own treatment, or replace clinical assessment.
Clinical notes: interpret the margin, then inspect the design
Noninferiority asks whether a new approach avoids being worse by more than an acceptable amount. For a lower-is-better outcome expressed as home minus outpatient, a positive difference favors outpatient care. Here, +1.2 lies below +10; the confidence interval also crosses zero. These answer different questions: meeting a noninferiority margin does not require showing superiority.
Eligibility required smartphone use. The trial was retrospectively registered, used imputation for missing outcomes and reported no per-protocol sensitivity analysis in the main text. Two authors were employees of the system's developer. No intervention-related adverse events were documented. The protocol, supplements, proprietary software and economic value were not independently audited.
As general appraisal principles, an acceptable margin needs clinical justification, and intention-to-treat analysis alone can be insufficiently reassuring in a noninferiority study if deviations make groups look similar. Follow-up completion also differs from exercise adherence. An active-comparator trial cannot by itself quantify benefit over receiving no treatment.
Primary neck-rehabilitation trial · Main report and displayed tables · DOI: 10.2196/87487
Make the plan understandable to the person using it
A new American Heart Association statement places health literacy across the stroke pathway, from prevention to recovery. Its central concern is the fit between communication demands and a person's ability to use the information. Its official summary assigns responsibility to healthcare teams and systems, rather than treating misunderstanding as a fixed patient deficit.
The statement discusses plain language, teach-back, patient-caregiver education and tailored digital support. Teach-back checks how clearly a plan was explained by asking the person to describe it in their own words. The goal is useful understanding, not a test that a patient must pass.
The AHA's actual “Top Things to Know” also distinguishes stroke-related communication deficits from limited health literacy. Aphasia, cognitive impairment, language access and digital skills can each change what support is needed. A fluent conversation or a signed instruction sheet does not establish that a plan will be usable at home.
Clinical notes: a scientific statement is not a new treatment trial
The primary abstract describes heterogeneous evidence, underpowered studies and inconsistent or insufficiently validated measures. This edition derives no pooled effect size, readmission reduction or universal screening threshold from it. The statement's complete journal text and its supporting trials remained unavailable after access attempts.
The official materials describe adapting communication and engaging the patient directly. A practical application is to agree how instructions should be presented, check understanding and revise the explanation where needed. These are communication principles; this edition does not claim that one particular script has been validated for every stroke survivor.
Primary AHA scientific-statement record · Actual official communication summary · DOI: 10.1161/STR.0000000000000537
A genetic result has to change treatment to change care
CYP2D6 is an enzyme involved in converting several opioids into more active compounds. Its activity can be influenced by inherited variation and by other medicines. A pragmatic trial tested whether giving clinicians CYP2D6-guided recommendations improved chronic-pain care for adults treated, or being considered for treatment, with tramadol, hydrocodone or codeine.
Of 1,048 enrolled participants, 282 had an actionable CYP2D6 phenotype. In that group, the change in composite pain intensity at three months was −0.8 (SD 2.4) with guidance versus −0.7 (SD 2.3) with usual care. Drug-gene concordance was 26.8% versus 27.1%. The abstract reports no improvement in pain or concordance and supplies no confidence interval for the pain comparison.
The practical limitation is fundamental: the recommendations did not change prescribing sufficiently to determine what would happen if the recommended changes were reliably implemented. This trial does not show that metabolism is irrelevant, nor that all pharmacogenetic testing improves pain care. It evaluates a particular guidance strategy in routine practice.
Clinical notes: implementation, phenotype and exploratory findings
The guidance considered both genotype and drug interactions. A person's functional enzyme phenotype can therefore differ from an inference based on genotype alone, a concept often called phenoconversion. Medication reconciliation remains part of interpreting the result; this report is not a stand-alone opioid-selection or dosing protocol.
An exploratory analysis associated treatment changes that matched phenotype with better pain scores. Whether patients actually received a concordant treatment was not itself a randomized assignment. That association can be confounded and cannot replace the primary randomized comparison. Complete allocation methods, implementation details, missing-data procedures, harms and precision estimates remained unavailable.
Primary CYP2D6-guided opioid trial · DOI: 10.1002/cpt.70505
A game can change practice; it still needs a meaningful outcome
A review of seven randomized trials involving 340 participants examined gamified or multicomponent gamified swallowing rehabilitation after stroke. The primary outcome was the Functional Oral Intake Scale (FOIS), a measure of the level of eating and drinking by mouth.
The pooled mean difference favored the gamified programmes: 1.53 FOIS points, 95% CI 0.58–2.49. However, I² was 96%, indicating very high variation between study results. A sensitivity analysis excluding one study retained a favorable average estimate, 1.04 points, 95% CI 0.46–1.61, while heterogeneity remained high at 85%.
Four trials contributed the secondary bedside swallowing assessment: mean difference −2.44, 95% CI −3.84 to −1.04. These score differences do not establish fewer episodes of aspiration pneumonia, improved survival or a safe diet for a particular person. The abstract does not provide those effects.
Clinical notes: ordinal scales, co-interventions and heterogeneity
A mean difference on an ordered functional scale is not a percentage increase in safe swallowing. Pooling also does not make every intervention identical: feedback, exercises, other treatment components and time after stroke varied. The abstract identifies several studies at high risk of bias and difficulty separating the game's contribution from other components.
The primary FOIS subgroup comparison did not demonstrate a clear difference according to surface-EMG use. Exploratory subgroup findings should not be turned into a device prescription. Searches ended December 22, 2025; this is an October 2026 report of an earlier evidence search. Full extraction tables, methods, complete harms and included trials were not independently appraised. Swallowing treatment and diet decisions still require an individualized clinical plan.
Primary post-stroke dysphagia meta-analysis · Publisher abstract and subscription preview · DOI: 10.1007/s00455-026-11014-6
An enlarged nerve is a finding that needs an explanation
Researchers reviewed ultrasound examinations of 76 patients with proximal upper-limb nerve injuries, covering 140 nerve segments. They assessed cross-sectional area at common distal entrapment sites and defined enlargement using published reference thresholds.
Distal enlargement appeared in 66 of 140 segments, 47.1%, and in 44 of 76 patients, 57.9%. These are different denominators. Several nerve observations could come from one patient; the larger segment count is not a second sample of independent people.
The finding encourages clinicians to inspect the nerve's course rather than assume that one proximal injury explains everything. It does not establish that every enlarged segment is a separate symptomatic compression, that enlargement caused the symptoms, or that treating that site improves recovery.
Clinical notes: structure, localization and treatment response
This was a retrospective, single-time-point dataset. It cannot establish whether enlargement preceded the injury, developed afterward or changes over time. Selection for ultrasound, reference thresholds and injury patterns may affect the observed proportions. The abstract supplies no control-group comparison, confidence intervals or validated surgical-selection rule.
For board study, separate four questions: what structure is abnormal, where the physiological lesion lies, which finding explains the clinical problem, and whether an intervention helps. Ultrasound morphology, clinical examination and electrodiagnostic localization contribute different information. A structural association alone does not answer the treatment question. Full clinical correlations and detailed measurement methods remained unavailable.
Primary proximal-injury and distal-enlargement study · DOI: 10.1002/pmrj.70237
Measure return to the role, as well as the scan
A trial enrolled military trainees with MRI-confirmed tibial or metatarsal bone stress injuries. All received standard care and were assigned active or sham photobiomodulation, a light-based treatment. 103 were randomized and 97 entered the final analysis.
The primary outcome was time to graduation, a concrete measure of return to the training role. The reported hazard ratio for sham versus active treatment was 0.95, 95% CI 0.61–1.48. There was no statistically clear difference. Only 37.1% of the analyzed cohort graduated on time, underscoring the practical burden of these injuries.
At four months, the abstract also reports no significant differences in on-time graduation or MRI healing: risk ratios 0.91, 95% CI 0.54–1.52, and 0.89, 95% CI 0.68–1.16, respectively. Pain and function comparisons were also uncertain.
Clinical notes: a null result, uncertainty and applicability
The primary interval includes potentially meaningful differences in either direction. A nonsignificant result does not prove zero effect, equal outcomes or adequate precision for every clinical decision. The trial nevertheless supplies no demonstrated advantage for routinely adding this treatment in this setting.
A cause-specific Cox analysis was reported for time to graduation. Its hazard ratio is not a percentage reduction in healing time. Training schedules, discharge from service and other competing events can matter to a role-based outcome, but their full handling was unavailable. Reasons for the six exclusions, treatment dose, complete harms and detailed eligibility also remained unavailable. Results in young military trainees should not be transferred automatically to older adults, osteoporotic fractures or other devices and dosing schedules.
Primary bone-stress-injury photobiomodulation trial · DOI: 10.1016/j.bone.2026.118135
Prescribe the activity and make room for the person's priorities
The new ACC exercise-prescription scientific statement calls for exercise to become a routine part of cardiovascular care, individualized to condition, function, symptoms, preferences and goals. Its primary abstract and the College's actual announcement were read; full statement access failed. The announcement supports combining aerobic and resistance activity and widening access to cardiac rehabilitation. This edition does not extract a disease-specific dose, testing algorithm or pooled effect from the unavailable full document. Primary statement record · Actual ACC announcement.
A Dutch cluster randomized trial tested a preference-elicitation tool alongside supervised exercise for intermittent claudication. It compared 1,199 intervention-group patients with 915 controls. Walking-distance outcomes did not improve significantly at three or six months. In sampled consultations, shared decision-making improved by a reported 39.0 points, while person-centeredness improved by 2.0 points; confidence intervals are absent from the abstract. A small quality-of-life difference favored controls at three months, but was not significant at six. Better participation in a decision and better walking performance are worthwhile but distinct outcomes. Only the primary abstract was appraised; cluster counts, scale context, full analysis and complete harms were unavailable. Primary preference-tool cluster trial.
Hidden ingredients and an exact-device alert
On October 15, FDA advised consumers not to buy or use 10 Day Forecast, a sexual-enhancement product. Laboratory testing found undeclared sildenafil and acetaminophen. Sildenafil can interact dangerously with nitrate medicines; hidden acetaminophen creates the possibility of unrecognized additional exposure and liver injury. This is a product-specific warning, not evidence that a label reliably identifies every ingredient in every supplement. The notice's text was reviewed; its product photograph was not. Actual FDA hidden-ingredient notification.
An FDA early alert posted in its October 15 device updates concerns Commander M delivery systems for SAPIEN M3 mitral-valve replacement, lots 67718561, 67804014, 67887043 and 67887044. It directs facilities not to use affected stock, to remove it from inventory and arrange returns; other lots are not affected. The concern is balloon bursting during delivery. Reports of one death and one serious injury were dated as of October 5, not a new October 16 event count. This notice concerns delivery equipment; it does not instruct patients to seek removal of an implanted valve. Actual FDA device alert.
For the education calendar, FDA and the Focused Ultrasound Foundation list a November 10 workshop, 9 a.m.–5 p.m. Eastern, on transcranial ultrasound, safety and clinical outcome assessment. The official description and preliminary agenda were read. Registration closes November 5 at 4 p.m. Eastern, subject to availability. A research workshop is not a new treatment approval, and this edition does not claim attendance, lecture review or CME credit. Official workshop description and registration details.
Test the interpretation
A trial compares home with outpatient care using a disability score where lower is better. The prespecified noninferiority margin is +10 points for home minus outpatient. The estimated difference is −2.5, with a 95% confidence interval from −6.2 to +1.2. Which interpretation best fits the reported comparison?
- Home care has proved superior because the point estimate is negative.
- Noninferiority failed because the confidence interval crosses zero.
- The interval meets the stated noninferiority criterion, but does not demonstrate superiority.
- The result proves that every home programme is equivalent to every clinic programme.
Reveal answer and reasoning
C. The upper limit, +1.2, is below the +10 margin, so the interval satisfies the stated criterion. Crossing zero means superiority is not demonstrated. Interpretation still depends on the margin's clinical acceptability, study conduct, missing data and the actual population and programme tested.
Words worth keeping
- Noninferiority margin
- The largest disadvantage a study defines as acceptable for a new treatment or delivery model.
- Confidence interval
- A range describing statistical uncertainty around an estimate under the analysis assumptions.
- Intention-to-treat analysis
- An analysis that keeps participants in their assigned groups, irrespective of what treatment they ultimately received.
- Health literacy
- The ability to find, understand and use health information and services, shaped also by how systems communicate and provide access.
- Teach-back
- Checking an explanation by asking a person to describe the plan in their own words.
- CYP2D6
- An enzyme involved in processing several medicines, including some opioids.
- Phenoconversion
- A change in functional drug-metabolizing activity, for example from an interacting medicine, compared with what genotype alone might suggest.
- Heterogeneity
- Variation between study results; it can limit how well a pooled average describes a particular setting.
- Cross-sectional area
- The area of a structure's slice, such as a nerve measured on an ultrasound image.
- Cluster randomized trial
- A trial that assigns groups such as practices or clinicians, requiring analysis to account for similarities within those groups.
References & the coverage record
- AI-Enabled Telerehabilitation for Chronic Nonspecific Neck Pain: Multicenter Randomized Controlled Trial. JMIR formative research · PMID 42879432 · DOI 10.2196/87487
- Health Literacy and Communication in Stroke Prevention, Management, and Recovery: A Scientific Statement From the American Heart Association. Stroke · PMID 42877955 · DOI 10.1161/STR.0000000000000537
- CYP2D6-Guided Opioid Therapy for Chronic Pain: A Multi-Center Pragmatic Randomized Controlled Trial. Clinical pharmacology and therapeutics · PMID 42878248 · DOI 10.1002/cpt.70505
- Effectiveness of Gamified Rehabilitation Interventions in Patients with Post-Stroke Dysphagia: A Meta-Analysis. Dysphagia · PMID 42875641 · DOI 10.1007/s00455-026-11014-6
- Ultrasound evidence of distal enlargement at entrapment sites following proximal peripheral nerve injury. PM & R : the journal of injury, function, and rehabilitation · PMID 42885094 · DOI 10.1002/pmrj.70237
- Photobiomodulation therapy versus sham for tibial and metatarsal bone stress injuries in military trainees: A randomized controlled trial. Bone · PMID 42880535 · DOI 10.1016/j.bone.2026.118135
- Exercise Prescriptions for Cardiovascular Health in Adults: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Journal of the American College of Cardiology · PMID 42878712 · DOI 10.1016/j.jacc.2026.09.008
- Implementation of a Guideline-Based Preference Elicitation Tool to Enhance Shared Decision-Making in Supervised Exercise Therapy for Patients With Intermittent Claudication: A Multi-Methods Cluster Randomized Trial. Physical therapy · PMID 42878725 · DOI 10.1093/ptj/pzag103
Six research reports and two scientific statements were appraised: a neck-pain randomized noninferiority trial, an AHA stroke communication statement, a pragmatic CYP2D6-guided opioid randomized trial, a dysphagia meta-analysis, a retrospective peripheral-nerve ultrasound study, an active-versus-sham bone-stress-injury trial, an ACC exercise-prescription statement and a preference-tool cluster randomized trial. The complete main neck-trial HTML, methods, displayed Tables 1–3, discussion, limitations and disclosures were read through verified publisher web access after direct requests returned empty content. Retrospective registration, the stated margin, imputation, absence of a reported per-protocol sensitivity analysis, smartphone eligibility and developer employment were noted. Original protocol, supplements, trial registry, source code, raw data and images were not independently audited; no economic or autonomous-AI benefit is claimed. The other seven primary journal items use abstracts; the dysphagia publisher page provides a subscription preview rather than complete methods. Actual AHA overview and Top Things to Know and the actual ACC announcement were read as official summaries, not as substitutes for the complete statements or their underlying trials. Complete statement access failed. No detailed exercise dosing or testing algorithm is inferred. All 88 registered-source statuses, all 15 domain results, 161 newly retrieved article titles/dates and 38 portal comparisons were inspected. All 12 unavailable sources were retried without recovery. Portal changes included merchandise links, a service-navigation link, food-recall items and generic publisher navigation, not verified educational chapter updates. FDA drug and device update lists were inspected beyond the registered landing pages. The actual October 15 hidden sildenafil/acetaminophen notification, Commander M early alert and transcranial-ultrasound workshop description and preliminary agenda were read. Product images, original manufacturer letters, detailed device attachments and workshop presentations were not reviewed. Device event counts are explicitly as of October 5; the listed alert date is distinct. The earlier NICE osteoarthritis page and AAPM&R course page were retrieved but are not used for new clinical claims or credited as course attendance. Discovery includes 811 journal-article metadata records and one book identifier, with all 15 domain results capped at 20 and truncated. A focused 21-record search was screened; selected primary abstracts were appraised, while older publications, protocols, preclinical studies and irrelevant reports were separated from new results. A primary cerebral-palsy garment trial had no PubMed abstract and inaccessible publisher content; no findings are asserted from its title. Metadata and landing-page checks do not establish exhaustive full-content coverage or absence of updates. Licensed chapters, paid courses, podcasts and recordings were unavailable or unreviewed. No physician review is recorded, no CME is granted and the study question is original educational material.
The discovery window was 2026/09/16–2026/10/16. A journal index check can miss work not yet indexed. A retrieved landing page does not verify every linked publication, paid course, podcast or textbook chapter. Candidate counts are discovery records, not validated practice changes.
See every registered source and its status → · Download this edition’s machine-readable coverage record
Educational, not medical advice. Discuss treatment choices with your clinician. Sources and evidence evolve; each dated edition preserves what was checked for that issue.